Introduction
Malignant lymphoma is the 5 th most common cancer in the United States with the incidence increasing in the past 3 decades. While some of the more aggressive forms of non-Hodgkin lymphoma (NHL) may at times be cured with combination chemoimmunotherapy, many patients with lymphoma eventually succumb to their disease.
Initial attempts to improve the outcome of lymphoma patients were based on intensifying therapy by adding additional chemotherapy agents or shortening the interval between doses. In aggressive lymphoma, these approaches initially improved survival and established CHOP chemotherapy as the standard treatment approach. Further attempts to add additional drugs to the frontline combinations did not result in additional benefit.
Intensifying CHOP by decreasing the time between doses added only modest benefit in a subset of patients and significantly increased toxicity. In low-grade histologies, have been dissected and reveal multiple potential targets for new agents 1 . These advances in our understanding have spawned a number of clinical investigations of novel agents, a number of which now appear to have clinically relevant single agent activity in malignant
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From lymphoma (see table 1 ). For the field of therapy to be advanced beyond current standards, novel agents need to be examined as additions to standard treatments and in unique combinations. Multiple new anti-CD20 antibodies are being developed to improve on the efficacy of rituximab. This review however will focus on novel agents, other than monoclonal antibodies, that have shown the most promise for future therapy of B-cell lymphoma.
Agents targeting the tumor microenvironment
Historically, the predominant approach to cancer therapy has been to develop agents that specifically inhibit the growth of the malignant cell. This selective inhibition has largely relied on the fact that the malignant cell proliferates faster than normal cells or expresses certain proteins more abundantly than non-malignant cells. More recent data have shown that the tumor microenvironment may also be a valid therapeutic target as surrounding normal cells may provide support for the malignant cell. Studies have shown that lymph nodes involved by malignant lymphoma commonly contain an admixture of nonneoplastic T-cells, dendritic cells, macrophages and stromal elements 2 3 . These studies have found that CD4+ T-cells (including follicular helper T-cells 4 and regulatory T-cells 5 , cytotoxic CD8+ T-cells 6 , macrophages 7 , dendritic cells 8 and intratumoral microvessels 9 ) all play a role in malignant cell growth. Targeting these supporting cells using drugs that modify the immune response may provide a novel therapeutic opportunity.
a. Immunomodulatory Drugs
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The immunomodulatory (IMiD) class of agents has already established a role in the treatment of myelodysplastic syndrome and multiple myeloma. Lenalidomide and pomalidomide are derived from the parent compound thalidomide and carry more potent activity (as measured in vitro inhibition of TNFα) as well as altered toxicity profiles.
Mechanism of action:
The exact mechanism of IMiD activity is unclear and may be different for different diseases. Much of what is known comes from data in myeloma cell lines. IMiDs have been shown to be anti-proliferative, and in higher doses lenalidomide and pomalidomide can cause off target myelosuppression. The direct antiproliferative effects may be due to down regulation of NFκB 10 and direct stimulation of the intrinsic apoptotic pathway.
IMiDs also inhibit the STAT3 and MAPK signaling pathways. Lenalidomide inhibits the Akt pathway 11 and increases the expression the tumor suppressor gene p21 12 . The IMiDs may also exert their effect by immune modulation. IMiDs stimulate T/NK cell activity in vitro and data suggests that this may be important in triggering tumor cell apoptosis 13 .
Lenalidomide has 2000 times more inhibitory effect on TNFα secretion by monocytes in vitro than thalidomide 14 but an increase in TNFα levels is seen in treated MM patients, presumably due to T-cell stimulation 15 . In a subgroup analysis 21 , the OR in FL was 32% and in SLL was 22%. The single agent activity in this relapsed setting has led to new trials adding lenalidomide to combinations of active agents as will be discussed below.
IMiD toxicity
The newer thalidomide analogs because of their chemical structure are presumed to be teratogenic but this has not been proven. Regardless, great precaution must be taken to avoid exposing a fetus to these agents. Thrombosis, which has been a major concern in the multiple myeloma population, has not yet been shown to be a significant issue in the lymphoma studies, albeit that aspirin has been used frequently for prophylaxis. Unlike thalidomide, lenalidomide and pomalidomide cause myelosuppression that is dose
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b. Targeting regulatory T-cells using Denileukin Diftitox
Denileukin Diftitox (Dd) is a fusion protein, composed of interleukin-2 (IL-2) binding sequences and active fragments of diphtheria toxin. It was approved for treatment of CD 25+ cutaneous T-cell lymphoma (CTCL) several years ago and is now being investigated in treatment of other lymphomas. Because CD25+ naturally-occurring regulatory T-cells (T reg cells) are highly expressed in B-cell lymphoma and suppress other intratumoral immune cells 6 , the use of Dd to deplete T reg cells may be of clinical benefit.
Mechanism of activity
Dd was designed to target cells expressing CD25 (TAC), the high affinity IL-2 receptor which is present on activated T-cells, B-cells, NK cells and macrophages. Ex-vivo studies suggest that Dd binds to high and medium affinity IL-2 receptors. The molecule is internalized and the toxin released, resulting in inhibition of protein synthesis and cell death.
Use in lymphoma
Dd is approved for use in CD25+ CTCL that is refractory or persistent after prior therapy.
Interestingly, patients whose CTCL was CD25 negative also had responses (31%)
suggesting off-target effects. This agent was therefore also tested in B-cell lymphomas. 
Toxicity of Denileukin Diftitox
Vascular leak syndrome with edema and low serum albumin though this is uncommon and mild if patients are pre-medicated with antihistamines and corticosteroids.
Transaminase elevation and fatigue can occur. Dd is not myelosupressive and in combination with other drugs has not shown any unexpected toxicity.
Inhibiting signaling pathways
Multiple signaling pathways appear to play a significant role in lymphoma growth and survival (see Figure 1 ). 
Toxicity of PCI-32765
Most toxicities were reportedly < grade 2
b. JAK/STAT pathway
The Janus kinase 2 (JAK2)/ signal transducers and activators of transcription (STAT)
pathway play an important role in the pathogenesis of hematological malignancies.
Activating mutations in the JAK2 gene has been reported in many myeloproliferative disorders but are rare in lymphoma. The STAT pathway however appears activated in lymphomas and may be suppressed by small molecule inhibitors such as SB1518.
Mechanism of activity
SB1518 is an orally bioavailable inhibitor of JAK2 and the JAK2 mutant JAK2V617F
with antineoplastic activity. SB1518 competes with JAK2 for ATP binding thereby inhibiting JAK2 activation. It also inhibits the JAK-STAT signaling pathway and promotes caspase-dependent apoptosis. The JAK-STAT signaling pathway is a major mediator of cytokine activity and inhibition of this pathway may suppress cytokines in the tumor microenvironment that promote tumor cell growth.
Use in lymphoma
In a phase 1 study of SB1518 in patients with relapsed lymphoma, patients were treated at doses up to 400 mg orally daily 29 . Eighteen patients are enrolled and 3 patients at the 300 mg dose level demonstrated disease response (1 follicular lymphoma, 1 small lymphocytic lymphoma and 1 mantle cell lymphoma). Eleven patients (73%) had stable disease. The effect of drug treatment on pJAK2, pSTAT3, and pSTAT5 was examined and SB1518 inhibited the JAK/STAT pathway as early as 4 hours after administration.
Toxicity of SB1518
The common grade1-2 AE's were diarrhea and constipation in 40%, and 13% developed grade 3 neutropenia. 
Toxicity of CAL-101
The dose limiting toxicity was transaminitis.
2) AKT Inhibitors
Perifosine is a novel oral agent in a new class of cancer therapies, the alkylphospholipids.
It is a synthetic oral agent that blocks activation of AKT, a key intracellular kinase involved in cell survival and proliferation. Toxicity of Perifosine GI symptoms of some degree occurred in over 65% in the phase II trial. While grade 3-4 hematologic toxicity was uncommon, grade 1-2 anemia and neutropenia were seen in 65% and 49% respectively.
3) mTOR inhibitors
Mammalian target of rapamycin (mTOR) is a central component in signaling of normal and malignant cell processes such as growth and proliferation. Inhibition of mTOR leads to cell death. There are currently four mTOR inhibitors in the clinic: rapamycin (sirolimus), and the rapalogs, temsirolimus (CC-779), everolimus (RAD001) and deforolimus. Temsirolimus and deforolimus are intravenous agents, while everolimus and sirolimus can be administered orally.
Mechanism of action
The PI3-K pathway is often dysregulated in human cancers due to mutation or loss of PTEN, mutation of PI3-K or amplification of AKT (PKB) 34 . mTOR is a downstream target of the PI3-K/AKT pathway and is represented by two components, mTORC1 and mTORC2. Only the mTORC1 component is inhibited by rapamycin and the rapalogs and it appears that mTORC2 is activated by pathways distinct from PI3-K/AKT. mTOR activation by AKT leads to cell proliferation and survival by modulating protein synthesis of critical molecules such as cyclin D1. mTOR signaling also activates NF-κB induced survival pathways 35 . The rapalogs are specific inhibitors of mTOR and in vitro can induce cell death. Inhibition of mTOR can sometimes lead to up-regulation of AKT by negative feedback and this may be a possible mechanism of resistance to the rapalogs.
Use in lymphoma.
Temsirolimus (CCI-779) was studied in relapsed MCL as a single agent given once stomatitis. An uncommon development has been the appearance of interstitial pneumonitis on routine follow-up CT scans.
e. Ras pathway inhibitors
The Ras/Raf/MEK1/2 (mitogen-activated kinase 1/2)/MAPK (mitogen-activated protein kinase) pathway is one of the most frequently dysregulated signaling cascades in cancer. 
Activating mutations of Ras and Raf occur frequently in both solid tumors and
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Mechanism of action
The Ras pathway is involved in multiple cellular processes, including cell proliferation, differentiation, and transformation. However, for the Ras protein to function, prenylation (farnesylation) is required. Ras then activates Raf, MEK1/2, ERK1/2 and MAPK.
Furthermore, there is accumulating evidence that cross talk between this pathway and various other signaling pathways exists 43 . These findings have resulted in the clinical development of small molecule inhibitors targeting specific components of the Ras/MAPK pathway, including farnesyltransferase inhibitors (e.g., tipifarnib), Raf-1
inhibitors (e.g., sorafenib), and MEK1/2 inhibitors (e.g., AZD6244, TAK-733) 44 .
Use in lymphoma.
The oral farnesyltransferase inhibitor, tipifarnib, has been used to treat patients with relapsed diffuse large, follicular grade III or mantle cell lymphoma 45 . Of the 38 patients who were evaluated, 18 percent had partial response, and 21 percent had stable disease. A second study in mantle cell lymphoma showed 1 response out of 11 patients treated (9%) 46 .
The multi-kinase inhibitor sorafenib (BAY 43-9006) was initially developed as a Raf-1 inhibitor, but has subsequently been shown to inhibit multiple other kinases, including FLT3, PDGFR, VEGFR1 and VEGFR2 47 . Sorafenib has been approved for the treatment of advanced renal cell carcinoma and hepatocelluar carcinoma. It has in vitro activity in lymphoma and multiple myeloma cell lines but has not been studied as a single agent in vivo.
For
Toxicity of Ras Inhibitors
Tipifarnib causes myelosuppression. Sorafenib side effects include hand-foot syndrome, rash, fatigue, anorexia and diarrhea.
f. Protein kinase C (PKC) inhibition
Protein kinase C beta (PKCβ) plays a pivotal role in normal B-cell signaling and survival.
Overexpression of PKCβ is implicated in the pathogenesis of B-cell lymphoma and has prognostic significance in diffuse large B-cell lymphoma 48 . Enzastaurin, an oral serine/threonine kinase inhibitor, targets the PKCβ as well as the PI3K/AKT pathways to inhibit tumor cell proliferation, induce apoptosis, and suppress tumor-induced angiogenesis.
Mechanism of action PKC-â is the major PKC isoform expressed by normal and malignant B lymphocytes and its activity is pivotal for survival signals triggered by the B-cell receptor 49 . In addition to the direct effects on tumor cells, PKC and PKC-â signaling pathways are also linked to VEGF-induced angiogenesis 50 . The antiangiogenic activity of PKC inhibitors may therefore represent an important functional aspect of these compounds. In fact, the antiangiogenic effect of enzastaurin has been demonstrated in several preclinical B-cell malignancy models 51, 52 .
Use in lymphoma.
Responses to single agent enzastaurin in patients with aggressive lymphomas have been rare. However, enzastaurin has appeared to prolong the time to progression in these patients. Similarly, in 60 patients with mantle cell lymphoma, no objective tumor
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From responses occurred, but 22 patients (37%) were free from progression for >3 months; 6 of 22 were free from progression for >6 months; and 2 patients remain on treatment and free from progression at >2 years 53 . In contrast, patients with follicular lymphoma have had higher response rates when treated with enzastaurin. Of 64 follicular lymphoma patients treated in a phase 2 trial, 1 (1.6%) had a complete response, 15 (23.4%) had partial response, for an overall RR of 25% 54 . The median DOR had not been reached (59-687 days).
Toxicity of Enzastaurin
Grade 3-4 adverse events are uncommon and in general it is well tolerated.
g. NFκB modulation utilizing Proteasome Inhibitors
The proteasome has been identified as a novel target in cancer cells given the role it plays in cell cycling, growth and survival. The proteasome is responsible for the degradation of 
Mechanism of activity:
While bortezomib clearly inhibits the proteasome, there is some controversy as to the mechanism of its anti-tumor activity. In multiple myeloma it has long been accepted that Btz acted by inhibition of NF-κB, a transcriptional factor that has been associated with .
Toxicity of proteasome inhibitors
The most common grade 3+4 adverse events with Btz are neuropathy (up to 50% of patients experience some symptoms), fatigue (12%) and thrombocytopenia (11%).
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New agents to promote apoptosis a. HDAC Inhibitors
Over expression and under expression of certain genes are hallmarks of malignant cells 
Use in lymphoma
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In a Phase II trial including many advanced hematologic cancers, a subgroup of 13 relapsed Hodgkin lymphoma patients received LBH589 in a dose of either 20 mg po three days per week or every other week and 5/13 had a partial response 64 . In a more recent study, Younes et al 65 showed an OR of 18% (1 CR, 10 PR) in a group of heavily treated relapsed HL patients. LBH589 is now being studied in B-cell NHL and in combination with other novel agents and will be discussed below.
MGCD0103 is a new oral HDACi. In a phase II trial for relapsed NHL, Crump et al 66 showed an OR of 14% (8/ 68 presented results of a phase II relapsed/refractory NHL trial that included follicular, mantle cell and mantle zone subtypes. The dose was 200 mg po BID, the same as is used in therapy of CTCL. An overall response of 29% was seen and 37% of the follicular and MZL patients responded.
HDAC inhibitor toxicity
The HDACi's have similar toxicities, the most common being fatigue, nausea, thrombocytopenia and neutropenia. Grade ≥ 3 toxicities occur in less than <30% of patients.
b. Bcl-2 Inhibitors
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Toxicity of Bcl-2 inhibitors
Myelosuppression, especially thrombocytopenia has been seen with most of these agents.
Obatoclax causes CNS symptoms of euphoria and somnolence during infusion but no lasting toxicity has been seen.
New Agents targeting DNA synthesis a. Bendamustine
A bifunctional alkylating agent first developed in East Germany over 40 years ago, Bendamustine has now been studied in North America and has received approval for treatment of CLL and more recently, relapsed indolent NHL failing or progressing within 6 months after Rituximab-based therapy. It is currently approved in Europe for treatment of NHL, Hodgkin lymphoma, CLL and multiple myeloma.
Mechanism of action
The chemical structure of bendamustine suggests the possibility of both alkylator-like activity as well as that of purine nucleosides. Furthermore, in vitro and in vivo data show non-cross resistance to commonly used alkylators such as cyclophosphamide and chlorambucil. This agent activates p53-dependent stress pathways leading to apoptosis and inhibits mitotic checkpoints. DNA damage is more extensive and it occurs with slower and different DNA repair pathways than other alkylators 72, 73 .
Use in lymphoma
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A phase II trial of bendamustine in rituximab refractory or intolerant, indolent or transformed lymphoma showed an overall response of 77% 74 . Patients received a dose of 120 mg/m2 days 1 and 2, q 3 weeks and received up to 6 cycles. Responses were seen in alkylator-refractory (61%) and fludarabine refractory (62%) patients, confirming the in vitro data that suggested non-cross resistance. Of the 74 evaluable patients, there were 34% CR/CRu and 43% PR with a median duration of response 6.6 months. In a second study presented by Kahl 75 100 patients with Rituximab-refractory indolent lymphoma were treated with the same schedule and dose. The OR was 84% with 32% CR/CRu and 52% PR. Again, alkylator refractory patients responded.
Toxicity of Bendamustine
Grade 3 or 4 neutropenia (54%) and thrombocytopenia (25%) are not unexpected. Nonhematologic toxicity however is mild with nausea, fatigue, diarrhea and vomiting being the most common.
b. Pralatrexate
This agent is a new anti-folate that more selectively targets the tumor cell than methotrexate. It has shown significant activity in T-cell lymphomas.
Mechanism of action
Pralatrexate, like other anti-folates interfere with DNA synthesis and cell replication by reversibly inhibiting dihydrofolate reductase, which prevents formation of necessary purine nucleotides. It is cell cycle specific (S phase). Early study showed pralatrexate to be more effectively internalized in malignant cells than methotrexate due to the presence of the reduced folate carrier, which is expressed only in malignant and fetal tissue 76 . Once internalized, it is polyglutamylated resulting in intracellular accumulation. It is less effective as an inhibitor of dihydrofolate reductase than methotrexate but because of its greater intracellular accumulation it has more anti-tumor activity and theoretically, less toxicity in normal tissue.
Use in Lymphoma
Pralatrexate was studied in a PhI/II trial by O'Connor et al 77 where 20 patients with relapsed/refractory non-Hodgkin and Hodgkin lymphoma were treated. The MTD was determined to be 30m/m2 q week X 6 out of 7 weeks. Of 4 patients with T-cell disease, all achieved a CR. There was stable disease at best in patients with B-cell disease.
Toxicity of Pralatrexate
Phase I study showed mucositis to be the DLT and occurs in 21% to 59% of patients, even in lower dose schedules. This seems to be more common in NHL than in lung cancer patients. Thrombocytopenia is seen in 33%, while anemia and neutropenia are less common (12% and 11% respectively).
Utilizing New Drugs in Rational Combinations
As outlined above, multiple new agents targeting various pathways important for malignant cell growth have shown clinical activity in lymphoma as single agents.
Unfortunately, in these studies a minority of patients responded and the duration of benefit was short-lived. Clearly, combining these agents with other effective therapy may enhance the combination resulting in greater benefit for lymphoma patients.
a. Combining new agents with rituximab
The anti-CD20 monoclonal antibody rituximab has become a standard of care as a single agent in indolent B-cell lymphoma patients with a relatively low burden of disease. assessing the true benefits of these combinations will be proven only in randomized studies.
b. Adding new agents to established lymphoma regimens
In the past decade, the addition of rituximab to combination chemotherapy has improved response rates, time to progression and overall survival in B-cell NHL. Despite this progress, many patients still relapse and outcomes with this chemo-immunotherapy approach may be improved if new agents are added to these combinations. Proteasome inhibition can be safely added to alkylator based therapies and several combinations have encouraging results: Combinations include Btz + R-CVP 84 , Btz + R-CHOP 85 , Btz + Fludarabine and rituximab 86 , Btz + Cyclophosphamide, dexamethasone and rituximab (CyBorD-R, C.T.gov NCT00711828), Btz + Hyper-CVAD 87 , and Btz + rituximab and bendamustine 88, 89 . Given the single agent activity of lenalidomide in both indolent and aggressive NHL, current trials are testing the benefit of adding it to established regimens.
At our institution we are completing trials with lenalidomide added to R-CHOP (R2-CHOP) for newly diagnosed aggressive lymphoma and to cyclophosphamide, rituximab and dexamethasone (LR-CD) for low grade lymphoma, including Waldenstrom's macroglobulinemia. Multi-institutional studies are testing maintenance lenalidomide after R-CHOP therapy.
c. Using combinations of new agents
Because many of the new agents selectively inhibit specific cell signaling pathways, combining agents that inhibit different mechanisms of cell growth and survival is particularly attractive. Our institution is currently piloting a combination of lenalidomide and the mTOR inhibitor RAD001 in a phase I trial, postulating that the different mechanisms of activity will be complementary.
Another rational approach would be inhibiting Ras/Raf/MEK and mTOR pathways: sorafenib is being tested in combination with the mTOR inhibitor everolimus and in an initial study of 26 patients, an overall response rate of 33% was seen with 2
CRs and 5 PRs 90 . Since sorafenib is non-myelosppressive, it could be combined with more standard, often myelosuppressive regimens as well as lenalidomide, a Btk inhibitor or Bcl-2inhibitor.
Patients who fail mTOR inhibitors often have upregulation of AKT so the combination of RAD001 or temsirolimus plus perifosine would be of interest. Realizing that the HDACi LBH589 also inhibits AKT, we are studying the combination of RAD001 plus panobinostat (LBH589) in a phase I trial for NHL (submitted to ASH 2010). The addition of an HDACi to Btz is another rational combination as has been explored in patients with relapsed refractory multiple myeloma.
Summary
We are optimistic that many of these novel agents may play a role in the future management of B-cell lymphoma. Indeed with as many as 8-9 new agents showing hints or clear evidence of activity in lymphoma it is highly likely that modern paradigms will evolve rapidly in the next few years. The optimal combinations of these drugs with existing agents and the most efficacious timing of use may be best directed when an individual's lymphoma targets are identified by gene profiling and immunohistochemistry. While rational combinations are developed, we must keep in
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In the current management of multiple myeloma, novel agents have extended the survival from a dismal 3 years to well over 5 years and importantly, many of those agents appear to be active in malignant lymphoma. The novel agents hold great promise for improving the outcomes of treatment and perhaps achieving the ultimate goal of curing malignant lymphoma. 
